Artemisinin Combination Therapy Market Size, Share & Trends Report

Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-2-68038-592-2
Number of Report Pages: 100
Format: PDF

Historical Range: 2018 - 2022
Forecast Period: 2024 - 2030
Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
  1.2. Market Definitions
  1.3. Research Methodology
1.3.1. Information Procurement
  1.3.2. Information or Data Analysis
  1.3.3. Market Formulation & Data Visualization
  1.3.4. Data Validation & Publishing
  1.4. Research Scope and Assumptions
  1.4.1. List of Data Sources
Chapter 2. Executive Summary
  2.1. Market Outlook
  2.2. Segment Outlook
  2.3. Competitive Insights
Chapter 3. Artemisinin Combination Therapy Market Variables, Trends, & Scope
  3.1. Market Introduction/Lineage Outlook
  3.2. Market Size and Growth Prospects (USD Million)
  3.3. Market Dynamics
  3.3.1. Market Drivers Analysis
  3.3.2. Market Restraints Analysis
  3.4. Artemisinin Combination Therapy Market Analysis Tools
  3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
  3.4.1.2. Bargaining power of the buyers
  3.4.1.3. Threats of substitution
  3.4.1.4. Threats from new entrants
  3.4.1.5. Competitive rivalry
  3.4.2. PESTEL Analysis
  3.4.2.1. Political landscape
  3.4.2.2. Economic and Social landscape
  3.4.2.3. Technological landscape
  3.4.2.4. Environmental landscape
  3.4.2.5. Legal landscape
Chapter 4. Artemisinin Combination Therapy Market: Type Estimates & Trend Analysis
  4.1. Segment Dashboard
  4.2. Artemisinin Combination Therapy Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  4.3. Artemether+Lumefantrine
  4.3.1. Artemether+Lumefantrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.4. Artesunate+Amodiaquine
  4.4.1. Artesunate+Amodiaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.5. Dihydroartemisinin+Piperaquine
  4.5.1. Dihydroartemisinin+Piperaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.6. Artesunate+Mefloquine
  4.6.1. Artesunate+Mefloquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.7. Artesunate+Sulfadoxine-Pyrimethamine
  4.7.1. Artesunate+Sulfadoxine-Pyrimethamine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.8. Pyronaridine-Artesunate
  4.8.1. Pyronaridine-Artesunate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  4.9. Other
  4.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Artemisinin Combination Therapy Market: Regional Estimates & Trend Analysis
  5.1. Artemisinin Combination Therapy Market Share, By Region, 2023 & 2030 (USD Million)
  5.2. North America
  5.2.1. North America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.2.2. U.S.
  5.2.2.1. U.S. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.2.3. Canada
  5.2.3.1. Canada Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.2.4. Mexico
  5.2.4.1. Mexico Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3. Europe
  5.3.1. Europe Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.2. U.K.
  5.3.2.1. U.K. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.3. Germany
  5.3.3.1. Germany Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.4. France
  5.3.4.1. France Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.5. Spain
  5.3.5.1. Spain Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.6. Italy
  5.3.6.1. Italy Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.7. Sweden
  5.3.7.1. Sweden Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.8. Norway
  5.3.8.1. Norway Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.3.9. Denmark
  5.3.9.1. Denmark Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4. Asia Pacific
  5.4.1. Asia Pacific Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4.2. China
  5.4.2.1. China Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4.3. Japan
  5.4.3.1. Japan Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4.4. India
  5.4.4.1. India Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4.5. South Korea
  5.4.5.1. South Korea Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4.6. Australia
  5.4.6.1. Australia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.4.7. Thailand
  5.4.7.1. Thailand Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.5. Latin America
  5.5.1. Latin America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.5.2. Brazil
  5.5.2.1. Brazil Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.5.3. Argentina
  5.5.3.1. Argentina Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.6. Middle East and Africa
  5.6.1. Middle East and Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.6.2. Saudi Arabia
  5.6.2.1. Saudi Arabia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.6.3. UAE
  5.6.3.1. UAE Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.6.4. South Africa
  5.6.4.1. South Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  5.6.5. Kuwait
  5.6.5.1. Kuwait Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
  6.1. Recent Developments & Impact Analysis by Key Market Participants
  6.2. Company Categorization
  6.3. Company Heat Map Analysis
  6.4. Company Profiles
  6.4.1. Advanced Micro Devices
  6.4.1.1. Participant’s Overview
  6.4.1.2. Financial Performance
  6.4.1.3. Product Benchmarking
  6.4.1.4. Recent Developments/ Strategic Initiatives
  6.4.2. Novartis AG
  6.4.2.1. Participant’s Overview
  6.4.2.2. Financial Performance
  6.4.2.3. Product Benchmarking
  6.4.2.4. Recent Developments/ Strategic Initiatives
  6.4.3. Sanofi S.A.
  6.4.3.1. Participant’s Overview
  6.4.3.2. Financial Performance
  6.4.3.3. Product Benchmarking
  6.4.3.4. Recent Developments/ Strategic Initiatives
  6.4.4. Cipla Ltd.
  6.4.4.1. Participant’s Overview
  6.4.4.2. Financial Performance
  6.4.4.3. Product Benchmarking
  6.4.4.4. Recent Developments/ Strategic Initiatives
  6.4.5. KPC Pharmaceuticals
  6.4.5.1. Participant’s Overview
  6.4.5.2. Financial Performance
  6.4.5.3. Product Benchmarking
  6.4.5.4. Recent Developments/ Strategic Initiatives
  6.4.6. Fosun Pharmaceutical (Guilin Pharmaceutical)
  6.4.6.1. Participant’s Overview
  6.4.6.2. Financial Performance
  6.4.6.3. Product Benchmarking
  6.4.6.4. Recent Developments/ Strategic Initiatives
  6.4.7. Ajanta Pharma
  6.4.7.1. Participant’s Overview
  6.4.7.2. Financial Performance
  6.4.7.3. Product Benchmarking
  6.4.7.4. Recent Developments/ Strategic Initiatives
  6.4.8. Ipca Laboratories Ltd.
  6.4.8.1. Participant’s Overview
  6.4.8.2. Financial Performance
  6.4.8.3. Product Benchmarking
  6.4.8.4. Recent Developments/ Strategic Initiatives
  6.4.9. Desano Inc.
  6.4.9.1. Participant’s Overview
  6.4.9.2. Financial Performance
  6.4.9.3. Product Benchmarking
  6.4.9.4. Recent Developments/ Strategic Initiatives
  6.4.10. Hovid Berhad
  6.4.10.1. Participant’s Overview
  6.4.10.2. Financial Performance
  6.4.10.3. Product Benchmarking
  6.4.10.4. Recent Developments/ Strategic Initiatives
  6.4.11. Mylan
  6.4.11.1. Participant’s Overview
  6.4.11.2. Financial Performance
  6.4.11.3. Product Benchmarking
  6.4.11.4. Recent Developments/ Strategic Initiatives

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.